Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Nanexa: New evaluation agreement in mAb space - ABG

Nanexa

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Signs evaluation agreement with "large global pharma company"
To evaluate PharmaShell in depot formulation of monoclonal antibody
Not a new field for Nanexa: already generated promising mAb data


New evaluation agreement with large global pharma company

Nanexa has announced today that it has signed a new Material Transfer and Feasibility Study Agreement agreement with a large global pharmaceutical company (company undisclosed). The agreement is to evaluate PharmaShell in a depot formulation of a monoclonal antibody.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.